Soluble mesothelin-related peptides (SMRP) are a potential tumor marker for malignant mesothelioma. The aim of this study was to determine the differences in SMRP levels in patients with malignant mesothelioma before treatment and in various responses to treatment and to investigate whether SMRP level could be useful in evaluating tumor response to treatment. The study included patients with malignant mesothelioma treated at the Institute of Oncology Ljubljana between March 2007 and December 2009. Blood samples were collected before treatment and/or in various responses to treatment. SMRP levels were determined using ELISA assay based upon a combination of two monoclonal antibodies. Mann-Whitney test was used to determine the differences in SMRP levels in various responses to treatment.Median SMRP was 2.80 nmol/L (range 0.00–34.80) before treatment, 0.00 nmol/L (range 0.00–0.00) in complete response, 0.48 nmol/L (range 0.00–4.40) in partial response, 1.65 nmol/L (range 0.00–20.71) in stable disease and 7.15 nmol/L (range 0.44–31.56) in progressive disease. Pre-treatment SMRP levels were significantly higher than in stable disease, partial response and complete response (p=0.006), as were SMRP levels in progressive disease compared to stable disease, partial response and complete response (p = 0.006), as were SMRP levels in progressive disease compared to stable disease, partial response and complete response (p < 0.001).Our findings suggest that SMRP may be a useful tumor marker for detecting the progression of malignant mesothelioma and evaluating tumor response to treatment.

中文翻译：

---

恶性间皮瘤患者的可溶性间皮素相关肽水平。

可溶性间皮素相关肽 (SMRP) 是恶性间皮瘤的潜在肿瘤标志物。本研究的目的是确定恶性间皮瘤患者治疗前和各种治疗反应中 SMRP 水平的差异，并研究 SMRP 水平是否可用于评估肿瘤对治疗的反应。该研究包括在 2007 年 3 月至 2009 年 12 月期间在卢布尔雅那肿瘤研究所治疗​​的恶性间皮瘤患者。在治疗前和/或对治疗的各种反应中收集血液样本。SMRP 水平使用基于两种单克隆抗体组合的 ELISA 测定法确定。Mann-Whitney 检验用于确定不同治疗反应中 SMRP 水平的差异。中位 SMRP 为 2.80 nmol/L（范围 0.00-34. 80) 治疗前，完全缓解 0.00 nmol/L（范围 0.00–0.00），部分缓解 0.48 nmol/L（范围 0.00–4.40），稳定疾病 1.65 nmol/L（范围 0.00–20.71）和 7.15 nmol/ L（范围 0.44–31.56）在疾病进展中。治疗前 SMRP 水平显着高于疾病稳定、部分反应和完全反应（p = 0.006)，进展性疾病中的 SMRP 水平与疾病稳定、部分缓解和完全缓解相比 ( p = 0.006)，疾病进展中 SMRP 水平与疾病稳定、部分缓解和完全缓解相比也是如此 ( p < 0.001)我们的研究结果表明，SMRP 可能是一种有用的肿瘤标志物，可用于检测恶性间皮瘤的进展和评估肿瘤对治疗的反应。